Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer

Inclusion Criteria: * Pathologically/histologically confirmed non-small cell lung cancer (NSCLC), advanced (stage IIIB w/ effusion or IV). * Performance status of 0, 1, or 2 * Brain metastases must be clinically stable after treatment with surgery and/or radiotherapy * Must have received two prior systemic anti-cancer regimens for recurrent/ metastatic disease, including one platinum-containing regimen * Prior radiotherapy, chemotherapy and/or treatment with investigational agents is allowed provided that the patient has recovered from the treatment-related side effects to grade ≤1, and that at least 3 weeks has passed since the last dose * Required laboratory values demonstrating adequate bone marrow, kidney, liver, and blood clotting function. * Negative pregnancy test for women of childbearing potential within 7 days prior to study entry * Life expectancy of 3 months or more * Must tolerate intramuscular injections * No prior or concurrent use of estrogen replacement therapy * No concurrent use of cytotoxic, immunologic, hormonal, or investigational agent intended for the antitumor treatment of NSCLC Exclusion Criteria: * Prior therapy with any anti-EGFR therapy such as gefitinib (IRESSA), erlotinib (TARCEVA), vandetanib (ZD6474, ZACTIMA), or fulvestrant (FASLODEX), or an aromatase inhibitor * Clinically significant cardiac event such as myocardial infarction, superior vena cava syndrome, New York Heart Association (NYHA) classification of heart disease ≥ 2 within 3 months before entry * History of arrhythmia (multifocal premature ventricular contractions (PVCs), bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation), which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia * Presence of left bundle branch block * Congenital long QT syndrome, or 1st degree relative with unexplained sudden death under 40 years of age * History of QTc prolongation as a result from other medications that required discontinuation of that medication * QTc with Bazett's correction that is unmeasurable, or ≥ 480 msec on screening ECG * Potassium \<4.0 mmol/L despite supplementation, or potassium above the CTCAE grade 1 upper limit * Serum calcium above the CTCAE grade 1 upper limit * Magnesium below the normal range despite supplementation, or above the CTCAE grade 1 upper limit * Hypertension not controlled by medical therapy (systolic blood pressure greater than 160 mm Hg or diastolic blood pressure greater than 100 mm Hg) * Diagnosis of active interstitial lung disease * Currently active diarrhea that may affect drug absorption * Previous or current malignancies of other histologies within the last 5 years, with the exception of cervical carcinoma in situ and basal cell or squamous cell carcinoma of the skin * Concomitant use of medications that are potent inducers of CYP3A4 are not allowed within 2 weeks of study or during the study * Any unresolved toxicity greater than CTC grade 1 from previous anti-cancer therapy * Major surgery within 4 weeks, or incompletely healed surgical incision * Women who are currently pregnant or breast feeding * History of bleeding diathesis (ie, disseminated intravascular coagulation \[DIC\], clotting factor deficiency) * History of hypersensitivity to active or inactive excipients of fulvestrant (ie castor oil or Mannitol)